Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Subgroup Analysis of the Phase 3 PhALLCON Study of Ponatinib in Ph+ ALL

March 5th 2024

An expert on leukemia provides comprehensive insights on the subgroup analysis of the phase 3 PhALLCON study of ponatinib in Ph+ acute lymphoblastic leukemia.

Long-Term Results of the OPTIC Trial in CML

March 5th 2024

Focusing on chronic myeloid leukemia, James K. McCloskey, MD, reviews the long-term results of the OPTIC trial presented at ASH 2023.

Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

March 5th 2024

An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.

IMerge: Imetelstat in Patients With Lower-Risk MDS

March 5th 2024

The expert panel discusses abstracts surrounding the IMerge clinical trial on imetelstat in patients with lower-risk myelodysplastic syndromes.

Banerjee Discusses FDA Call for Secondary Malignancies Boxed Warning on CAR T-cell Therapies

March 4th 2024

Rahul Banerjee, MD FACP, discusses the FDA’s decision to add a class-wide boxed warning for secondary malignancies on all approved CAR T-cell therapies.

OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

March 1st 2024

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

Practical Advice for Management of Chronic GVHD

February 29th 2024

The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.

Quality of Life and Patient Reported Outcomes (PRO) in Chronic GVHD

February 29th 2024

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

FDA Approves Label Expansion for Oral Ibrutinib Suspension in All Current Indications

February 28th 2024

The FDA has approved a label expansion for ibrutinib with an oral suspension formulation in all current indications.

How Does GvHD Typically Present?

February 28th 2024

Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.

Overview of Graft-vs-Host Disease (GvHD)

February 28th 2024

Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.

Recent Data from ASH 2023 in Leukemia

February 27th 2024

Following ASH 2023, a hematologist-oncologist discusses recent updates on approved and emerging therapies for patients with leukemia, highlighting the TRANSFORM-1 trial looking at navitoclax plus ruxolitinib.

The Evolving Treatment Landscape of Leukemia

February 27th 2024

James K. McCloskey, MD, a specialist in leukemia, discusses how the treatment landscape has changed in recent years.

FDA Grants Priority Review to sBLA of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

February 27th 2024

The FDA has granted priority review to the sBLA of epcoritamab for relapsed/refractory follicular lymphoma.

Future Outlooks in the Treatment of R/R DLBCL

February 27th 2024

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

February 27th 2024

Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.

Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

February 27th 2024

Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.

Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS

February 27th 2024

Following ASH 2023, Andrew Brunner, MD, reviews key updates from the COMMANDS trial investigating frontline luspatercept in patients with lower-risk MDS.

The Future of CAR T-Cell Therapy in LBCL

February 27th 2024

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, look at both the regulatory and clinical components that will shape future research and utilization of CAR T-cell therapy in oncology and beyond.

VOD: Ensuring Best Outcomes

February 26th 2024

Experts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.